3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
36
Phase 1
22
Phase 3
19
Phase 1/2
14
Phase 4
1
Phase 2/3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Thymoma
1
Pancreatic Neoplasms
1
Lung Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Large Cell
1
Carcinoma
1
Advanced Gastric Cancer
1
Adenocarcinoma Pancreas
1
Adenocarcinoma
1
Interventions
Pemetrexed
10
Cisplatin
9
Erlotinib Hydrochloride
8
Carboplatin
7
icotinib
5
Gefitinib
5
Docetaxel
5
endostar protein
3
Zoledronic Acid
3
Radiotherapy
3
Paclitaxel
3
Gemcitabine
3
Endostatins
3
Afatinib
3
tislelizumab
2
pembrolizumab
2
osimertinib
2
lorlatinib
2
flurbiprofen axetil
2
dexamethasone 21-phosphate
2
atezolizumab
2
Vinorelbine
2
Surgical Procedures, Operative
2
Saline Solution
2
Nivolumab
2
Drug Therapy
2
Dexamethasone
2
Chemoradiotherapy
2
trametinib
1
spartalizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Carcinoma, Non-Small-Cell Lung
×
130-nm albumin-bound paclitaxel
×
Clear all
NCT02151149
2018-09-24
ABOUND 70+
Celgene
Phase 4
Completed
143 enrolled
25 charts